Q-omics provides the consensus-scored ZNF783 profile across patient tissues and cancer cell-line models. ZNF783 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF783 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ZNF783 RNA expression shows 20,235 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where ZNF783 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF783 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF783 survival associations across molecular data types. ZNF783 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF783 RNA expression–survival associations across cancer types. High ZNF783 expression shows unfavorable associations in KIRC, ACC, LIHC and COAD, but favorable associations in HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF783 RNA expression.
This table summarizes ZNF783 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF783. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF783 shows higher tumor expression in COAD, HNSC, LIHC, STAD, LUSC and LUAD. The COAD box plot shows higher ZNF783 RNA expression in tumor versus normal tissue (log2 FC = +1.132, t-test p < 0.001).
This table shows molecular features associated with ZNF783 in patient tissues and cancer cell lines. In patient samples, ZNF783 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF783 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
